Department of Sexual Health, Infectious Diseases and Environmental Health, South Limburg Public Health Service, Heerlen, Netherlands; Department of Medical Microbiology, Care and Public Health Research Institute, Maastricht University Medical Centre, Maastricht, Netherlands.
Department of Sexual Health, Public Health Service Haaglanden, The Hague, Netherlands.
Lancet Infect Dis. 2021 Jun;21(6):858-867. doi: 10.1016/S1473-3099(20)30594-6. Epub 2021 Jan 11.
Women are not routinely tested for oropharyngeal Neisseria gonorrhoeae. At present, selective testing based on sexual behaviour or risk groups is advocated by international guidelines. Many oropharyngeal infections are asymptomatic and thus remain undetected, establishing a reservoir for ongoing transmission. Data on effectiveness of routine testing are scarce, thus we aimed to assess the optimal testing strategy for oropharyngeal N gonorrhoeae in women.
In this retrospective cohort study, we used surveillance data obtained from all sexually transmitted infection (STI) clinics in the Netherlands between Jan 1, 2008, and Dec 31, 2017. We collected consultation-level data, and individual-level patient data from 2016 onwards, on sociodemographic characteristics, sexual behaviour in the past 6 months, self-reported symptoms, and STI diagnoses. We compared the prevalence of oropharyngeal N gonorrhoeae between women who attended clinics that offered routine universal testing (defined as >85% of women tested per clinic-year) and women who attended clinics that offered selective testing (defined as 5-85% of women tested per clinic-year) or incidental testing (<5% of women tested per clinic-year). We calculated the number of infections missed by selective testing by extrapolating prevalence for the routine universal testing group to that of weighted and unweighted samples of all selectively tested women. We used multivariable generalised estimating equations to identify independent risk factors for oropharyngeal N gonorrhoeae to identify the optimal selective testing strategy.
554 266 consultations with at least one N gonorrhoeae test were recorded, of which 545 750 consultations (including repeat visits) were included in the analyses. Of 545 750 consultations, routine universal testing was used in 57 359 (10·5%), selective testing in 444 283 (81·4%), and incidental testing in 44 108 (8·1%). The prevalence of oropharyngeal N gonorrhoeae was 1·4% (95% CI 1·3-1·5; 703 of 50 962 consultations) in the routine testing group compared with 1·4% (1·3-1·5; 1858 of 132 276) in the selective testing group (p=0·68) and 2·8% (1·9-3·9; 30 of 1088) in the incidental testing group (p<0·0001). The prevalence of oropharyngeal-only infections was 47·7% (335 of 703 women) in the routine testing group, 53·3% (991 of 1858) in the selective testing group, and 60·0% (18 of 30) in the incidental testing group. Selective testing would have missed an estimated 4363 (70%; 95% CI 69-71) of all 6221 oropharyngeal N gonorrhoeae infections. Independent risk factors for oropharyngeal N gonorrhoeae were being notified for any STI (adjusted odds ratio 2·1, 95% CI 1·5-3·0), reporting sex work (4·0, 2·3-6·7), and having concurrent genital (51·5, 34·1-77·7) or anorectal (2·6, 1·4-4·8) N gonorrhoeae. Selective testing of women notified for any STI, or who reported sex work, would have led to 5418 (27·8%) of 19 455 women being tested and would have identified 119 (55·6%) of 214 oropharyngeal N gonorrhoeae infections.
Selective testing potentially misses more than two-thirds of oropharyngeal N gonorrhoeae infections in women, of whom half have oropharyngeal infections without concurrent genital or anorectal infections. Using independent risk factors for oropharyngeal infection to guide testing is a minimal testing strategy. Routine universal testing is the optimum scenario to detect the majority of infections. However, future studies are needed to assess the cost-effectiveness of routine testing and its effect on antimicrobial resistance.
Public Health Service South Limburg.
女性通常不会接受咽淋病奈瑟菌的检测。目前,国际指南提倡根据性行为或风险群体进行选择性检测。许多咽感染无症状,因此未被发现,成为持续传播的储源。关于常规检测效果的数据很少,因此我们旨在评估女性咽淋病奈瑟菌的最佳检测策略。
在这项回顾性队列研究中,我们使用了 2008 年 1 月 1 日至 2017 年 12 月 31 日期间荷兰所有性传播感染(STI)诊所获得的监测数据。我们收集了咨询层面的数据,并从 2016 年开始收集个体层面的患者数据,包括社会人口统计学特征、过去 6 个月的性行为、自我报告的症状和 STI 诊断。我们比较了在常规普遍检测(定义为每个诊所年度检测的女性比例>85%)和选择性检测(定义为每个诊所年度检测的女性比例为 5-85%)或偶然检测(每个诊所年度检测的女性比例<5%)的诊所就诊的女性中咽淋病奈瑟菌的患病率。我们通过将常规普遍检测组的患病率外推到所有选择性检测女性的加权和未加权样本中来计算选择性检测遗漏的感染数量。我们使用多变量广义估计方程来确定咽淋病奈瑟菌的独立危险因素,以确定最佳的选择性检测策略。
记录了 554266 次至少有一次淋病奈瑟菌检测的咨询,其中 545750 次(包括复诊)被纳入分析。在 545750 次咨询中,常规普遍检测组 57359 次(占 10.5%),选择性检测组 444283 次(占 81.4%),偶然检测组 44108 次(占 8.1%)。常规检测组咽淋病奈瑟菌的患病率为 1.4%(95%CI 1.3-1.5;50962 次咨询中有 703 次),与选择性检测组的 1.4%(1.3-1.5;132276 次咨询中有 1858 次)(p=0.68)和偶然检测组的 2.8%(1.9-3.9;1088 次咨询中有 30 次)(p<0.0001)相比。常规检测组咽感染的患病率为 47.7%(703 名女性中有 335 名),选择性检测组为 53.3%(991 名女性中有 991 名),偶然检测组为 60.0%(30 名女性中有 18 名)。选择性检测组可能会遗漏所有 6221 例咽淋病奈瑟菌感染中的 4363 例(70%;95%CI 69-71)。咽淋病奈瑟菌的独立危险因素是报告任何 STI(调整后的优势比 2.1,95%CI 1.5-3.0)、报告性工作(4.0,2.3-6.7)和同时存在生殖器(51.5,34.1-77.7)或肛门直肠(2.6,1.4-4.8)淋病奈瑟菌。对报告任何 STI 的女性或报告性工作的女性进行选择性检测,将导致 19455 名女性中的 5418 名(27.8%)接受检测,并将发现 214 例咽淋病奈瑟菌感染中的 119 例(55.6%)。
选择性检测可能会遗漏女性咽淋病奈瑟菌感染的三分之二以上,其中一半有咽感染而无同时存在的生殖器或肛门直肠感染。使用咽感染的独立危险因素来指导检测是一种最小化的检测策略。常规普遍检测是检测大多数感染的最佳方案。然而,需要进一步研究来评估常规检测的成本效益及其对抗菌药物耐药性的影响。
南林堡公共卫生局。